SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 118 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,000 | -26.7% | 2,550 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $15,000 | +66.7% | 2,550 | +104.0% | 0.00% | +50.0% |
| Q4 2021 | $9,000 | -90.6% | 1,250 | -87.6% | 0.00% | -96.4% |
| Q1 2019 | $96,000 | -52.0% | 10,050 | -42.2% | 0.06% | -57.3% |
| Q4 2018 | $200,000 | +1.5% | 17,400 | +49.4% | 0.13% | +28.4% |
| Q3 2018 | $197,000 | +95.0% | 11,650 | +1.3% | 0.10% | +61.9% |
| Q2 2017 | $101,000 | -39.5% | 11,500 | -64.3% | 0.06% | -39.4% |
| Q1 2017 | $167,000 | +11.3% | 32,200 | -34.6% | 0.10% | +10.6% |
| Q4 2016 | $150,000 | -28.9% | 49,200 | +8.1% | 0.09% | -30.4% |
| Q3 2016 | $211,000 | -25.7% | 45,500 | -7.1% | 0.14% | -26.6% |
| Q2 2016 | $284,000 | +8.0% | 49,000 | +12.6% | 0.18% | +4.5% |
| Q1 2016 | $263,000 | +64.4% | 43,500 | +148.6% | 0.18% | +70.9% |
| Q4 2015 | $160,000 | – | 17,500 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |